Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Redefining Standards, Refining Psychiatry

Rhea-AI Summary

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) has been featured in an editorial by NetworkNewsWire, highlighting the growing interest in psychedelic therapies for treating chronic diseases. The company is advancing its clinical programs, focusing on synthetic psilocybin for neuropsychiatric disorders, with its lead candidate TRP-8802 aimed at fibromyalgia, impacting over five million Americans. Tryp is also preparing a phase 2a clinical study for eating disorders in collaboration with the University of Florida and is developing TRP-1001 for soft-tissue sarcomas, potentially qualifying for orphan drug status.

Positive

• Featured in an editorial by NetworkNewsWire, enhancing visibility.
• Advancing clinical programs in psychedelic therapies addressing chronic pain and eating disorders.
• Lead drug candidate TRP-8802 targets fibromyalgia, affecting over five million in the U.S.
• Preparing for phase 2a clinical study for eating disorders with University of Florida.
• Developing TRP-1001 for soft-tissue sarcomas, potentially eligible for orphan drug status.

Negative

• None.

NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases,“ please visit: https://ibn.fm/uFQY9

The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by investors that rode the cannabis wave seeing a brand-new opportunity with drugs such as psilocybin, LSD, MDMA, DMT, and others to address hard-to-treat mental health diseases, namely depression, addiction, post-traumatic stress disorder and anxiety. As strides are being made on those fronts, a second investment wave is swelling on the horizon that looks to feature expanded indications and bring new therapeutic options to diseases with unmet needs.

Psychedelics could redefine standards of care for chronic diseases and reshape psychiatry, including counseling practices, among other things. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is leading this next wave of psychedelic drug development beyond mental health into chronic pain and eating disorders as the company advances its clinical programs.

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.

For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYP are available in the company’s newsroom at https://ibn.fm/TRYPF.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is the significance of Tryp Therapeutics' feature in the NetworkNewsWire editorial?

The feature enhances Tryp Therapeutics' visibility and positions it as a key player in the psychedelic therapy market.

What clinical programs is Tryp Therapeutics advancing?

Tryp is advancing programs focused on synthetic psilocybin for neuropsychiatric disorders, fibromyalgia, and eating disorders.

What is TRP-8802 and its intended use?

TRP-8802 is Tryp's lead drug candidate aimed at treating fibromyalgia, a chronic pain syndrome.

What collaborative study is Tryp Therapeutics preparing for?

Tryp is preparing for a phase 2a clinical study for eating disorders in collaboration with the University of Florida.

What is the potential status of TRP-1001 in treating soft-tissue sarcomas?

TRP-1001 may qualify for orphan drug status due to its focus on rare soft-tissue sarcomas.